Next-generation sequencing and genetic diagnosis of Charcot-Marie-Tooth disease

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Over 70 different Charcot-Marie-Tooth disease (CMT)-associated genes have now been discovered and their number is growing. Conventional genetic testing for all CMT genes is cumbersome, expensive, and impractical in an individual patient. Next-generation sequencing (NGS) technology allows cost-effective sequencing of large scale DNA, even entire exome (coding sequences) or whole genome and thus, NGS platform can be employed to effectively target a large number or all CMT-related genes for accurate diagnosis. This overview discusses how NGS can be strategically used for genetic diagnosis in patients with CMT or unexplained neuropathy. A comment is made to combine simple clinical and electrophysiological algorithm to assign patients to major CMT subtypes and then employ NGS to screen for all known mutations in the subtype-specific CMT gene panel.

Original languageEnglish
Pages (from-to)383-386
Number of pages4
JournalAnnals of Indian Academy of Neurology
Volume17
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Charcot-Marie-Tooth Disease
Genes
Exome
Genetic Testing
Genome
Technology
Costs and Cost Analysis
Mutation
DNA

Keywords

  • CMT
  • exome
  • genetic testing
  • genome
  • next-generation sequencing

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Next-generation sequencing and genetic diagnosis of Charcot-Marie-Tooth disease. / Verma, Ashok.

In: Annals of Indian Academy of Neurology, Vol. 17, No. 4, 01.01.2014, p. 383-386.

Research output: Contribution to journalArticle

@article{0bc0f1fba21f4593989257a315017f13,
title = "Next-generation sequencing and genetic diagnosis of Charcot-Marie-Tooth disease",
abstract = "Over 70 different Charcot-Marie-Tooth disease (CMT)-associated genes have now been discovered and their number is growing. Conventional genetic testing for all CMT genes is cumbersome, expensive, and impractical in an individual patient. Next-generation sequencing (NGS) technology allows cost-effective sequencing of large scale DNA, even entire exome (coding sequences) or whole genome and thus, NGS platform can be employed to effectively target a large number or all CMT-related genes for accurate diagnosis. This overview discusses how NGS can be strategically used for genetic diagnosis in patients with CMT or unexplained neuropathy. A comment is made to combine simple clinical and electrophysiological algorithm to assign patients to major CMT subtypes and then employ NGS to screen for all known mutations in the subtype-specific CMT gene panel.",
keywords = "CMT, exome, genetic testing, genome, next-generation sequencing",
author = "Ashok Verma",
year = "2014",
month = "1",
day = "1",
doi = "10.4103/0972-2327.144004",
language = "English",
volume = "17",
pages = "383--386",
journal = "Annals of Indian Academy of Neurology",
issn = "0972-2327",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Next-generation sequencing and genetic diagnosis of Charcot-Marie-Tooth disease

AU - Verma, Ashok

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Over 70 different Charcot-Marie-Tooth disease (CMT)-associated genes have now been discovered and their number is growing. Conventional genetic testing for all CMT genes is cumbersome, expensive, and impractical in an individual patient. Next-generation sequencing (NGS) technology allows cost-effective sequencing of large scale DNA, even entire exome (coding sequences) or whole genome and thus, NGS platform can be employed to effectively target a large number or all CMT-related genes for accurate diagnosis. This overview discusses how NGS can be strategically used for genetic diagnosis in patients with CMT or unexplained neuropathy. A comment is made to combine simple clinical and electrophysiological algorithm to assign patients to major CMT subtypes and then employ NGS to screen for all known mutations in the subtype-specific CMT gene panel.

AB - Over 70 different Charcot-Marie-Tooth disease (CMT)-associated genes have now been discovered and their number is growing. Conventional genetic testing for all CMT genes is cumbersome, expensive, and impractical in an individual patient. Next-generation sequencing (NGS) technology allows cost-effective sequencing of large scale DNA, even entire exome (coding sequences) or whole genome and thus, NGS platform can be employed to effectively target a large number or all CMT-related genes for accurate diagnosis. This overview discusses how NGS can be strategically used for genetic diagnosis in patients with CMT or unexplained neuropathy. A comment is made to combine simple clinical and electrophysiological algorithm to assign patients to major CMT subtypes and then employ NGS to screen for all known mutations in the subtype-specific CMT gene panel.

KW - CMT

KW - exome

KW - genetic testing

KW - genome

KW - next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=84911018537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911018537&partnerID=8YFLogxK

U2 - 10.4103/0972-2327.144004

DO - 10.4103/0972-2327.144004

M3 - Article

AN - SCOPUS:84911018537

VL - 17

SP - 383

EP - 386

JO - Annals of Indian Academy of Neurology

JF - Annals of Indian Academy of Neurology

SN - 0972-2327

IS - 4

ER -